Archive · 10 Aug 2026
Indian stocks surge on realty deals, pharma approvals, rail contracts
This news is about money and companies in India.
A real estate company called Signature Global hired two other companies to build many apartment towers.
A bank called IndusInd Bank got permission to start a new business that helps people buy and sell stocks.
Some medicine companies made new deals or ended old ones, and one got permission to sell a new cancer medicine.
Railway companies signed big contracts to build tracks and infrastructure.
A power company won a contest to build big batteries that store electricity in West Bengal.
A food safety group stopped some whisky drinks from being sold because they used fake flavours instead of real ageing.
All of these are business decisions that companies announce to the stock market.
Signature Global awarded ₹920 crore construction contracts to KEC International and NCC for its 1,798-unit 'Sarvam at DXP Estate' project on Dwarka Expressway, Gurugram.
IndusInd Bank received RBI approval to set up a wholly owned stockbroking subsidiary; shares closed 1.9% higher at ₹1,025 on the BSE.
Novartis India terminated its Distribution and Promotion Agreement with Dr Reddy's Laboratories effective September 30, 2026, and AstraZeneca Pharma India received approval to import Enhertu for HER2-positive breast cancer.
NTPC Green Energy won 200 MW/800 MWh of BESS capacity in West Bengal at ₹4.35 lakh per MW per month, while Juniper Green Energy won a 230 MW project under SECI's round-the-clock tender.
FSSAI prohibited sales of Diageo's Royal Challenge Whisky made in Madhya Pradesh and some whisky and rum brands by Diageo and Inbrew for using artificial flavouring rather than proper ageing.
- Who
- Indian companies including Signature Global, KEC International, NCC, IndusInd Bank, Novartis India, Dr Reddy's Laboratories, AstraZeneca Pharma India, Gland Pharma, RITES, NTPC Green Energy, Juniper Green Energy, NBCC, Gamco, G R Infraprojects, Adani Enterprises, Diageo, Inbrew, and regulators RBI, USFDA, and FSSAI.
- What
- Multiple corporate announcements covering realty construction contracts, a bank's new stockbroking subsidiary, pharma deals and approvals, railway contracts and production, energy tender wins, property sales, and regulatory action against whisky brands.
- When
- Announcements published on August 10, 2026, with several events dated in 2026, including a USFDA inspection May 06-15, 2026, and Novartis-Dr Reddy's termination effective September 30, 2026.
- Where
- India, spanning Gurugram, Haridwar, Ratlam, New Delhi, Varanasi, West Bengal, Ahmedabad, and other Indian locations.
- Why
- Companies are executing growth strategies in real estate, banking, pharma, railways, and renewable energy, while the FSSAI acted to halt misleading and improperly flavoured spirits.
- Signature Global contracts
- Rs 920 crore — ₹460 crore to KEC International and ₹460 crore to NCC for 'Sarvam at DXP Estate' in Sector 37D, Dwarka Expressway, Gurugram
- Project details
- 11 residential towers, 1,798 units, ~5 million sq ft; construction starting by end of Q3 FY27
- IndusInd Bank share price
- Closed 1.9% higher at ₹1,025 on the BSE after RBI approval for stockbroking subsidiary
- USFDA inspection at Emcure Pharma
- Sanand, Ahmedabad facility inspected May 06-15, 2026; classified as Voluntary Action Indicated (VAI)
- NTPC Green Energy BESS win
- 200 MW/800 MWh in West Bengal at ₹4.35 lakh per MW per month via WBSEDCL e-reverse auction
- Juniper Green Energy win
- 230 MW under SECI's 1,000 MW firm-and-dispatchable RTC tender at ₹5.26 per unit
- NBCC e-auction
- ~2.34 lakh sq ft at Bharat Business Park, Sarojini Nagar, New Delhi sold for ~₹1,236 crore
- Gamco stake in Blissara Resorts
- Raised to 33.33% with ₹18.21 crore acquisition of additional 25.5% stake